Drug Profile
Anti-Ras antibody gene therapy
Alternative Names: AV1Y28 anti-Ras antibody gene therapyLatest Information Update: 05 Mar 2008
Price :
$50
*
At a glance
- Originator Introgen Therapeutics
- Developer Introgen Therapeutics; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Gene therapies
- Mechanism of Action Ras protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 04 Apr 2003 No development reported - Preclinical for Cancer in USA (unspecified route)
- 10 Jan 2001 Preclinical development for Cancer in USA (Unknown route)